Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Fulvestrant Approved at 500 mg in EU: AZ
April 19, 2010
- RDKK Launches Elecsys Reagent for RA
April 19, 2010
- Zeria Licenses Hemostatic, Wound Dressing Agents from HemCon
April 19, 2010
- Afinitor, Temodal Transiently Excluded from DPC Payment System
April 19, 2010
- Kobayashi Pharm. Spins Off Medical Device Division
April 19, 2010
- Bayer Integrates Intendis
April 19, 2010
- Requirements for Med Institutions Conducting Regenerative Medicine Notified
April 19, 2010
- Medwatcher Japan Presents Petition on Use of Unapproved Medical Devices
April 19, 2010
- CMIC Completes Acquisition of Daiichi Sankyo Propharma's Shizuoka Plant
April 19, 2010
- Q&A on Biosimilars Issued
April 19, 2010
- More than Just the Money
Philip Carrigan
Partner, Optia Partners
philip@optiapartners.com
April 19, 2010
- Alfresa to Tie Up with 4 Wholesalers
April 19, 2010
- Takeda to Enhance Training of Executives with Global Business Capabilities
April 19, 2010
- JSIM Introduces COI Self-Reporting Requirement from April 12
April 19, 2010
- MCI Provides Tablet PCs to All MRs from Benesis
April 19, 2010
- Gefitinib Effective for EGFR-Positive NSCLC in First-Line Therapy
April 19, 2010
- GSK to Disclose Payments to Physicians Made in 2009 and Onward
April 19, 2010
- 637 Monitors Certified in 2nd JCROA Monitor Certification Test
April 19, 2010
- Takeda Initiates Overseas PIII Trial of SGN-35 for Lymphoma
April 19, 2010
- Norvasc, Lipitor Most Often Co-prescribed But in Only 4.3% of Patients
April 19, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…